NCT05990192View on ClinicalTrials.gov

SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy

PHASE2RecruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

June 20, 2024

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions
Ovarian Cancer Recurrent
Interventions
DRUG

Niraparib oral capsule

Niraparib used following SBRT treatment until disease progression

RADIATION

SBRT

SBRT may be delivered using a specialist SBRT platform, such as CyberKnife or with a linear accelerator with SBRT capabilities.

Trial Locations (5)

EH4 2XU

RECRUITING

Western General Hospital, Edinburgh

SM2 5PT

RECRUITING

The Royal Marsden NHS Foundation Trust, Sutton

NW1 2PG

RECRUITING

University College London Hospitals, London

SW3 6JJ

RECRUITING

The Royal Marsden NHS Foundation Trust, London

M20 4BX

RECRUITING

The Christie NHS Foundation Trust, Manchester

All Listed Sponsors
collaborator

Royal Marsden NHS Foundation Trust

OTHER

lead

Institute of Cancer Research, United Kingdom

OTHER